Harmaline

Harmaline

SCHEMBL199260

COc1ccc2c3c([nH]c2c1)C(C)=NCC3

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 1.00
MEN1 O00255 7/20 1.00
KMT2A Q03164 7/20 1.00
CASP1 P29466 6/20 1.00
HTR7 P34969 6/20 1.00
MAPT P10636 6/20 1.00
CYP2D6 P10635 5/20 1.00
ALDH1A1 P00352 5/20 1.00
HPGD P15428 5/20 1.00
CASP7 P55210 5/20 1.00
HSD17B10 Q99714 5/20 1.00
CYP3A4 P08684 4/20 1.00
HTR2C P28335 4/20 1.00
TDP1 Q9NUW8 4/20 1.00
RECQL P46063 3/20 1.00
HTR2A P28223 3/20 1.00
HTR6 P50406 3/20 1.00
POLB P06746 3/20 1.00
GLA P06280 2/20 1.00
TSHR P16473 2/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Harmaline SCHEMBL29626541 1.00 KDM4E (1.00) KDM4EMEN1KMT2ACASP1HTR7
Harmaline SCHEMBL1360259 0.99 KDM4E (0.97) KDM4EMEN1KMT2ACASP1HTR7
Harmaline SCHEMBL177545 0.97 KDM4E (1.00) KDM4EMEN1KMT2ACASP1HTR7
Harmaline SCHEMBL30055802 0.97 KDM4E (1.00) KDM4EMEN1KMT2ACASP1HTR7
Harmaline SCHEMBL31500129 0.91 KDM4E (0.83) KDM4EMEN1KMT2ACASP1HTR7
Harmaline SCHEMBL9481244 0.89 KDM4E (0.80) KDM4EMEN1KMT2ACASP1HTR7
SCHEMBL3877767 0.89 KDM4E (1.00) KDM4EMEN1KMT2ACASP1HTR7
Harmaline SCHEMBL28061967 0.89 KDM4E (0.78) KDM4EMEN1KMT2ACASP1HTR7
SCHEMBL1520427 0.85 KDM4E (0.74) KDM4EMEN1KMT2ACASP1HTR7
SCHEMBL28871756 0.83 KDM4E (0.70) KDM4EMEN1KMT2ACASP1HTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2233 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260137652-A1 Composition Comprising Non-Phosphorylated Tryptamine SINTALICA S R L (IT) 2026-05-21 US claimed
US-20260091047-A1 THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS NATIVE CODE BIO LLC (US) 2026-04-02 US claimed
US-20260034065-A1 EXTENDED RELEASE PHARMACEUTICAL FORMULATION DOUGLAS PHARMACEUTICALS LTD (NZ) 2026-02-05 US claimed
US-20250360137-A1 ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES FREEDOM BIOSCIENCES INC (US) 2025-11-27 US claimed
US-20250360150-A1 METHODS OF USING NEUROPLASTIC AGENTS AND TERRAFORMING MARS BRANNOCK METCALF MOLLY CAROLINE (US) 2025-11-27 US claimed
US-12472146-B2 Extended release pharmaceutical formulation DOUGLAS PHARMACEUTICALS, LTD. (NZ) 2025-11-18 US claimed
US-20250339403-A1 Tryptamine Formulations and Uses Thereof Natural MedTech Pty Ltd (AU) 2025-11-06 US claimed
EP-4638419-A1 NON-HALLUCINOGENIC TRYPTAMINE COMPOUNDS, PREPARATION, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF Sintalica S.r.l. (IT) 2025-10-29 EP claimed
EP-4618981-A1 COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE Remedi, Inc. (US) 2025-09-24 EP claimed
EP-4618980-A1 ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES Freedom Biosciences, Inc. (US) 2025-09-24 EP claimed
EP-1303280-A1 ENHANCED BRAIN FUNCTION BY GABA-ERGIC STIMULATION University of Utah Research Foundation (US) 2003-04-23 EP claimed
US-20020192256-A1 Water miscible pesticide containing a synergistic cocktail of plant alkaloids GREENTECH, INC. 2002-12-19 US claimed
US-6372239-B1 Compositions and methods for controlling pests using synergistic cocktails of plant alkaloids GREENTECH, INC. 2002-04-16 US claimed
US-20020019421-A1 Compositions and therapy for substance addiction BIBERMAN RONI (IL) 2002-02-14 US claimed
WO-2002000221-A1 ENHANCED BRAIN FUNCTION BY GABA-ERGIC STIMULATION UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2002-01-03 WO claimed
WO-2001058263-A1 COMPOSITIONS AND METHODS FOR CONTROLLING PESTS USING SYNERGISTIC COCKTAILS OF PLANT ALKALOIDS GREENTECH, INC. (US) 2001-08-16 WO claimed
US-6114350-A Cyanine dyes and synthesis methods thereof NEN LIFE SCIENCE PRODUCTS, INC. (US) 2000-09-05 US claimed
US-5591738-A Method of treating chemical dependency using β-carboline alkaloids, derivatives and salts thereof NDA INTERNATIONAL, INC. (US) 1997-01-07 US claimed
US-5256533-A Preincubating sample with an alpha-2-inhibitor; comparing fluorescence in test to control tissues BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 1993-10-26 US claimed
WO-1991014184-A1 BETA CARBOLINES AS VITAL STAINS FOR NEUROTRANSMITTER SYSTEMS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 1991-09-19 WO claimed